Profilo
Dr. David Kao is a Vice President-Regulatory Affairs at Inhibrx Biosciences, Inc. Dr. Kao was previously employed as a Vice President-Regulatory Affairs by Inhibrx, Inc. and a Head-Development Program by Bristol Myers Squibb Co. He received his undergraduate degree from Rutgers State University of New Jersey, an MBA from Rutgers Business School and a doctorate degree from Shenandoah University.
Posizioni attive di David Kao
| Società | Posizione | Inizio |
|---|
Precedenti posizioni note di David Kao
| Società | Posizione | Fine |
|---|---|---|
| INHIBRX, INC. | Consigliere Generale | 30/05/2024 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formazione di David Kao
| Rutgers Business School | Masters Business Admin |
| Shenandoah University | Doctorate Degree |
| Rutgers State University of New Jersey | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Aziende private | 1 |
|---|---|
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
- Borsa valori
- Insiders
- David Kao
